Showing 2623 results
- https://www.novartis.com/news/media-releases/sandoz-biosimilar-filgrastim-recommended-approval-fda-oncologic-drugs-advisory-committeeOncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US Biosimilar filgrastim recommended to be approved for use in all requested…
- https://www.novartis.com/news/media-releases/novartis-collaborates-intellia-therapeutics-and-caribou-biosciences-explore-making-medicines-and-drug-discovery-tools-crispr-genome-editing-technologyCollaborations give Novartis access to novel CRISPR technology platforms for the discovery and development of new medicines Intellia Therapeutics collaboration to explore therapeutic options for…
- https://www.novartis.com/news/media-releases/fda-approves-sandoz-erelzitm-treat-multiple-inflammatory-diseasesErelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine Erelzi is approved for all indications included in the reference product's…
- https://www.novartis.com/news/media-releases/novartis-convenes-experts-discuss-new-technologies-healthcare-novartis-international-biocamp13th International Biotechnology Leadership Camp focuses on potential of new technologies to fundamentally transform biomedical research and the pharmaceutical business Interactive program…
- https://www.novartis.com/news/media-releases/experten-diskutieren-am-novartis-international-biocamp-neue-technologien-im-gesundheitsbereichIm Zentrum des 13. International Biotechnology Leadership Camp steht das Potenzial neuer Technologien, die biomedizinische Forschung und die Pharmabranche grundlegend zu verändern Das interaktive…
- https://www.novartis.com/news/media-releases/sandoz-publishes-supplement-listing-prospectus-including-sandoz-h1-2023-financial-statementsAd hoc announcement pursuant to Art. 53 LRSupplement published by Sandoz ahead of Novartis Extraordinary General Meeting on September 15, 2023H1 results demonstrated continued momentum with strong…
- https://www.novartis.com/news/media-releases/sandoz-publie-un-supplement-au-prospectus-de-cotation-comprenant-les-etats-financiers-de-sandoz-au-premier-semestre-2023Annonce ad hoc en vertu de l’art. 53 LRSupplément publié par Sandoz avant l’Assemblée générale extraordinaire de Novartis du 15 septembre 2023Les résultats du premier semestre ont…
- https://www.novartis.com/news/media-releases/sandoz-veroffentlicht-nachtrag-zum-kotierungsprospekt-einschliesslich-finanzabschluss-von-sandoz-fur-das-1-halbjahr-2023Ad-hoc-Mitteilung gemäss Art. 53 LRNachtrag von Sandoz veröffentlicht vor der ausserordentlichen Generalversammlung von Novartis am 15. September 2023Die Ergebnisse des ersten…
- https://www.novartis.com/news/media-releases/novartis-convie-plusieurs-experts-au-novartis-international-biocamp-afin-de-discuter-des-nouvelles-technologies-en-matiere-de-santeLa 13e édition de l'International Biotechnology Leadership Camp explore les nouvelles technologies susceptibles de révolutionner la recherche biomédicale et l'industrie pharmaceutique. Un programme…
- https://www.novartis.com/news/media-releases/novartis-announces-positive-phase-iii-results-showing-efficacy-baf312-patients-secondary-progressive-msThe Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS) met its primary endpoint of reducing the risk of three-month confirmed disability progression…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 263
- › Next page